297 related articles for article (PubMed ID: 25645689)
21. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ
Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299
[TBL] [Abstract][Full Text] [Related]
22. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Rees JN; Florang VR; Anderson DG; Doorn JA
Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells.
Watabe M; Nakaki T
Mol Pharmacol; 2008 Oct; 74(4):933-40. PubMed ID: 18599602
[TBL] [Abstract][Full Text] [Related]
24. Impaired dopamine metabolism in Parkinson's disease pathogenesis.
Masato A; Plotegher N; Boassa D; Bubacco L
Mol Neurodegener; 2019 Aug; 14(1):35. PubMed ID: 31488222
[TBL] [Abstract][Full Text] [Related]
25. 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
Neurochem Res; 2016 Sep; 41(9):2173-8. PubMed ID: 27220335
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
[TBL] [Abstract][Full Text] [Related]
27. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
Burke WJ
Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):143-8. PubMed ID: 12769806
[TBL] [Abstract][Full Text] [Related]
28. Catechols in post-mortem brain of patients with Parkinson disease.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC
Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636
[TBL] [Abstract][Full Text] [Related]
29. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
Fitzmaurice AG; Rhodes SL; Lulla A; Murphy NP; Lam HA; O'Donnell KC; Barnhill L; Casida JE; Cockburn M; Sagasti A; Stahl MC; Maidment NT; Ritz B; Bronstein JM
Proc Natl Acad Sci U S A; 2013 Jan; 110(2):636-41. PubMed ID: 23267077
[TBL] [Abstract][Full Text] [Related]
30. Increased striatal dopamine turnover following acute administration of rotenone to mice.
Thiffault C; Langston JW; Di Monte DA
Brain Res; 2000 Dec; 885(2):283-8. PubMed ID: 11102582
[TBL] [Abstract][Full Text] [Related]
31. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.
Jinsmaa Y; Florang VR; Rees JN; Mexas LM; Eckert LL; Allen EM; Anderson DG; Doorn JA
Chem Biol Interact; 2011 Jun; 192(1-2):118-21. PubMed ID: 21238438
[TBL] [Abstract][Full Text] [Related]
32. In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.
Crawford RA; Bowman KR; Cagle BS; Doorn JA
Neurotoxicology; 2021 Sep; 86():85-93. PubMed ID: 34314733
[TBL] [Abstract][Full Text] [Related]
33. The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
Goldstein DS
Semin Neurol; 2020 Oct; 40(5):502-514. PubMed ID: 32906170
[TBL] [Abstract][Full Text] [Related]
34. DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells.
Jinsmaa Y; Sullivan P; Sharabi Y; Goldstein DS
Auton Neurosci; 2016 Jan; 194():46-51. PubMed ID: 26777075
[TBL] [Abstract][Full Text] [Related]
35. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
Goldstein DS; Kopin IJ; Sharabi Y
Pharmacol Ther; 2014 Dec; 144(3):268-82. PubMed ID: 24945828
[TBL] [Abstract][Full Text] [Related]
36. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
[TBL] [Abstract][Full Text] [Related]
37. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
Mattammal MB; Haring JH; Chung HD; Raghu G; Strong R
Neurodegeneration; 1995 Sep; 4(3):271-81. PubMed ID: 8581559
[TBL] [Abstract][Full Text] [Related]
38. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease.
Michel TM; Käsbauer L; Gsell W; Jecel J; Sheldrick AJ; Cortese M; Nickl-Jockschat T; Grünblatt E; Riederer P
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S68-72. PubMed ID: 24262192
[TBL] [Abstract][Full Text] [Related]
39. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.
Rees JN; Florang VR; Eckert LL; Doorn JA
Chem Res Toxicol; 2009 Jul; 22(7):1256-63. PubMed ID: 19537779
[TBL] [Abstract][Full Text] [Related]
40. [Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)].
Bonnet JJ; Legros H; Janin F; Dourmap N; Costentin J
Ann Pharm Fr; 2004 Sep; 62(5):323-31. PubMed ID: 15314580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
